

CLAIM AMENDMENTS

1. (Currently amended) A method of blocking microbial adherence to a eukaryotic cell surface in a mammal by applying to said surface a pharmaco logically acceptable composition comprising consisting essentially of isoleucine present in a microbial blocking quantity.
2. (Original) The method of claim 1 wherein the microbial blocking quantity is in the range of from about 0.1 ug/cm² to about 1 gm/cm² of eukaryotic cell surface area.
3. (Original) The method of claim 2 wherein said quantity is from about 3 ug/cm² to about 100 ug/cm².
4. (Original) The method of claim 2 wherein said quantity is from about 10 ug/cm² to about 100 ug/cm².
5. (Original) The method of claim 1 wherein the mammal is man.
6. (Original) The method of claim 1 wherein the epithelial surface is one or more of the oral cavity, GI tract, respiratory tract, genitourinary tract, skin, eye, and vaginal/cervical area.
7. (Original) The method of claim 1 wherein the composition consists of a pure powder of L(+)-isoleucine and/or DL-isoleucine.
8. (Original) The method of claim 1 wherein the composition is in the form of a dry powder, a paste, a solution, a gel, a tablet, a lozenge, or a capsule.
9. (Previously amended) The method of claim 1 wherein the composition is directly applied to the epithelial said surface.

10. (Previously amended) The method of claim 1 wherein the composition is in the form of a pharmacologically acceptable aqueous composition containing from about 0.01 ug/ml to about 50 ug/ml of isoleucine.

11. (Previously amended) A pharmacologically acceptable composition comprising :

- A) from about 0.001 to about 99% by weight of a compound consisting essentially of isoleucine;
- B) at least one additional pharmacologically active substance; and, optionally,
- C) pharmacologically acceptable carrier materials and/or excipients.

12. (Original) The composition of claim 11 wherein component A) is present in from about 0.002 to about 50% by weight.

13. (Original) The composition of claim 11 wherein component A) is present in from about 0.1 to about 25% by weight.

14. (Original) The composition of claim 11 wherein said composition is in the form of a dental care product.

15. (Original) The composition of claim 14 wherein component B) is one or more of a fluoride, xylitol, an antibody, and an anti-microbial agent.

16. (Original) The composition of claim 14 wherein the composition is in the form of a toothpaste or a gel.

17. (Cancelled)

18. (Previously amended) A toothpaste or gel comprising a eukaryotic cell surface blocking quantity of a compound consisting essentially of isoleucine.

19-24 (Cancelled)

25. (Currently amended) The composition of claim 24_11 wherein component B) is an antifungal and/or antimicrobial substance.

26-30 (Cancelled)

31. (Previously amended) The composition of claim 11 wherein the composition is in the form of a wound ointment or cream, and component B) is one or more of an antimicrobial substance and anesthetic.

32. (Previously amended) A wound ointment or cream comprising a eukaryotic cell surface blocking quantity of a compound consisting essentially of isoleucine.

33. (Cancelled)

34. (Original) The composition of claim 11 wherein the composition is in the form of a skin ointment or cream.

35-40 (Cancelled)